<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geoffrey S Gottlieb, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John A Bartlett, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H13491378"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Although HIV-1 infection is associated with most of the global AIDS pandemic, HIV-2 is an important cause of infection and disease in certain regions of the world where it is endemic, most notably West Africa. People living with HIV-2 infection can be found in most countries and regions globally, so it is an important consideration in patients with an AIDS-like illness [<a href="#rid1">1</a>]. </p><p>This topic will address the epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection. The clinical manifestations, diagnosis, and treatment of HIV-2 are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16727.html" rel="external">"Clinical manifestations and diagnosis of HIV-2 infection"</a> and  <a class="medical medical_review" href="/z/d/html/16252.html" rel="external">"Treatment of HIV-2 infection"</a>.)</p><p class="headingAnchor" id="H1426447"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>As of the end of 2021, the Joint United Nations Programme on HIV and AIDS (UNAIDS) and the World Health Organization (WHO) estimate that approximately 38.4 million people are living with HIV/AIDS; by crude estimates, approximately one to two million of these people are living with HIV-2 [<a href="#rid2">2-5</a>], including some who are dually infected with both viruses [<a href="#rid2">2-4,6-8</a>].</p><p class="headingAnchor" id="H1427234"><span class="h2">Origin of the epidemic</span><span class="headingEndMark"> — </span>Serologic evidence of a second human immunodeficiency virus was first discovered in 1985 in Senegal [<a href="#rid9">9</a>] with subsequent isolation of HIV-2 documented in 1986 from a Cape Verdean patient [<a href="#rid10">10</a>]. Similar to HIV-1, HIV-2 was initially a zoonosis, originally transmitted from West African Sooty mangabeys (<em>Cercocebus atys</em>) to humans [<a href="#rid11">11-13</a>]. Serologic data suggest that HIV-2 may have been circulating as early as 1966 [<a href="#rid14">14</a>] while phylogenetic evidence dates its introduction into humans during the first half of the 20<sup>th</sup> century [<a href="#rid15">15,16</a>]. (See  <a class="medical medical_review" href="/z/d/html/3036.html" rel="external">"Global epidemiology of HIV infection", section on 'Origin of the HIV pandemic'</a>.)</p><p class="headingAnchor" id="H1427152"><span class="h2">HIV-2 in West Africa</span><span class="headingEndMark"> — </span>HIV-2 is endemic in West Africa, although data over the past decade suggest that epidemiologic trends may be shifting [<a href="#rid17">17-19</a>]. Several African countries (eg, Senegal, Gambia, Cote D’Ivoire, Guinea-Bissau) have reported declining prevalence rates of HIV-2 over time [<a href="#rid17">17-22</a>].</p><p>As an example, a cross-sectional survey performed from 1996 to 2006 among 3242 individuals living in Guinea-Bissau demonstrated that the incidence of HIV-2 was declining and was half that of HIV-1 infection, when compared with a similar serosurvey from 1987 to 1996 [<a href="#rid19">19,23</a>].</p><p>Additionally, the prevalence of HIV-2 decreased among persons below 45 years of age, but not among older individuals [<a href="#rid19">19</a>]. This observation may be due to a cohort effect, where previously infected individuals are aging with HIV-2 infection, which is less pathogenic than HIV-1 [<a href="#rid19">19</a>]. Other explanations include: a) lower rates of sexual transmission of HIV-2 compared with HIV-1 and b) screening of the blood supply for HIV-2, which was initiated in 1987. (See <a class="local">'Transmission'</a> below.)</p><p class="headingAnchor" id="H1427159"><span class="h2">HIV-2 outside West Africa</span><span class="headingEndMark"> — </span>Regions and countries outside of West Africa reporting HIV-2 infections include: North America (United States, Canada), South America and Caribbean (Brazil, Columbia, Argentina, Venezuela, Cuba), Europe (France, Spain, Portugal, United Kingdom, Sweden, Germany, Italy, Switzerland, Netherlands, Belgium, Greece, Turkey, Russia), the Middle East (Lebanon, Israel, Egypt, Saudi Arabia), Asia-Oceania (India, Pakistan, Philippines, China, Nepal, Japan, South Korea, Australia, New Zealand), and southern, central, and northern Africa (Zimbabwe, Angola, Mozambique, South Africa, Gabon, Equatorial Guinea, Democratic Republic of the Congo, Morocco) [<a href="#rid2">2,24</a>]. </p><p>In the United States, the first case of HIV-2 infection was reported in 1987 [<a href="#rid25">25</a>]. The total number of cases of HIV-2 in the United States is small, with only 166 cases reported to the United States Centers for Disease Control and Prevention (CDC) between 1987 and 2009 [<a href="#rid26">26</a>]. In updated surveillance data from 2010 to 2017, only 198 of 327,700 (0.06 percent) of new HIV diagnoses reported to the CDC were due to HIV-2; of these, patients were classified as having HIV-2 monoinfection (102), dual HIV-1 and HIV-2 infection (11), or probable but unconfirmed HIV-2 infection (85) [<a href="#rid27">27</a>]. Most experts suspect the number of HIV-2 infections is a likely underestimate; there have been 46 cases of HIV-2 diagnosed in New York City between 2010 and 2020 (three had dual HIV-1/HIV-2 infection); in addition, 25 had probable HIV-2 infection [<a href="#rid28">28</a>]. Many other urban areas (eg, Chicago, Boston, Washington, DC) also include immigrants from West Africa where HIV-2 is endemic [<a href="#rid1">1,29</a>]. The prevalence of HIV-2 may also be underestimated since most people living with HIV-2 are asymptomatic and may never have been tested for HIV infection. </p><p class="headingAnchor" id="H1426891"><span class="h2">Dual infection with HIV-1 and HIV-2</span><span class="headingEndMark"> — </span>Dual infection with HIV-1 and HIV-2 can occur in locales where both viruses cocirculate [<a href="#rid6">6-8</a>]. Dual infection has been reported most commonly in West Africa where it is estimated that approximately 5 to 10 percent of individuals with HIV are coinfected with HIV-2 [<a href="#rid3">3,20,30-33</a>]. </p><p>Although one observational study in Senegalese female sex workers suggested that HIV-2 infection may be protective against HIV acquisition [<a href="#rid34">34</a>], these results were not corroborated by subsequent reports [<a href="#rid35">35-37</a>]. </p><p class="headingAnchor" id="H1427133"><span class="h1">TRANSMISSION</span></p><p class="headingAnchor" id="H60762404"><span class="h2">Routes of transmission</span><span class="headingEndMark"> — </span>HIV-1 and HIV-2 share similar routes of transmission including sexual contact, blood-borne exposure (eg, blood transfusions, shared needles) and perinatal transmission. </p><p>Screening of the blood supply has virtually eliminated transmissions via this route in developed countries [<a href="#rid38">38</a>]. The risk of HIV-2 infection has also declined in some African countries, such as Guinea-Bissau, Senegal, and Cote d'Ivoire, where HIV screening of the blood supply was initiated early in the HIV epidemic [<a href="#rid23">23,39,40</a>].</p><p class="headingAnchor" id="H60762411"><span class="h2">Risk of transmission</span><span class="headingEndMark"> — </span>Transmission of HIV-2 appears to be less efficient than HIV-1 [<a href="#rid41">41-47</a>]. This is particularly notable when comparing perinatal transmission rates for these two viruses [<a href="#rid48">48</a>]. For example, in studies of pregnant women in The Gambia or the Ivory Coast, the relative risk of transmission was 6- to 21-fold lower among women with HIV-2 compared to those with HIV-1 [<a href="#rid43">43,47</a>].</p><p>The lower risk of transmission of HIV-2 may be related to lower levels of viremia that are seen among infected patients compared with those with HIV-1. Compared with HIV-1, lower levels of HIV-2 shedding have also been found in the genital tracts of men and women, which may also help to explain the lower rates of HIV-2 transmission through sexual contact [<a href="#rid41">41,45,49</a>]. (See <a class="local">'Natural history'</a> below.)</p><p class="headingAnchor" id="H13491385"><span class="h1">NATURAL HISTORY</span></p><p class="headingAnchor" id="H151845"><span class="h2">HIV-2 is less pathogenic than HIV-1</span><span class="headingEndMark"> — </span>Multiple studies suggest that HIV-2 is generally less pathogenic than HIV-1. Chronic HIV-1 infection is characterized by rising levels of viremia and progressive immunologic decline in association with opportunistic infections that eventually lead to death in untreated persons. Compared with HIV-1, HIV-2 infection is characterized by [<a href="#rid41">41-46,49-58</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>A longer asymptomatic stage of infection </p><p class="bulletIndent1"><span class="glyph">●</span>Slower declines of CD4+ T cell counts</p><p class="bulletIndent1"><span class="glyph">●</span>Lower levels of plasma viremia in chronically infected patients </p><p></p><p class="headingAnchor" id="H60761993"><span class="h3">Risk of AIDS</span><span class="headingEndMark"> — </span>The slower natural history of HIV-2 infection was well illustrated in an observational study in Senegal; 46 commercial sex workers with HIV-1 infection and 103 with HIV-2 infection were recruited and followed serially from 1985 to 1993 [<a href="#rid51">51</a>]. Over the course of the study, the probability of AIDS-free survival was higher among HIV-2 compared with HIV-1 infected women (100 percent versus 67 percent). In addition, a subset of women with incident HIV-1 seroconversion (n = 32) were significantly more likely to have a decline in CD4 cell counts (&lt;400 cells/microL) than those with incident HIV-2 seroconversion (n = 33). In a natural history study comparing HIV-1 and HIV-2 in 872 patients from Guinea-Bissau, with 23 years of follow-up, the median time from HIV infection to development of AIDS was significantly longer in those with HIV-2 (14.3 versus 6.2 years) [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H2601006"><span class="h3">Risk of death</span><span class="headingEndMark"> — </span>Persons with HIV-2 infection and a CD4 count &gt;500 cells/microL appear to have a lower risk of dying compared to those with HIV-1 infection and a similar immune status [<a href="#rid59">59</a>]. However, mortality rates among patients with HIV-1 and HIV-2 infection with advanced disease appear similar when adjusting for CD4 cell count, age, and sex [<a href="#rid57">57</a>]. </p><p>Several studies have evaluated the risk of death in persons living with HIV-2 [<a href="#rid60">60-63</a>]. A meta-analysis that included seven studies comparing HIV-1- versus HIV-2-monoinfected individuals reported a mortality rate ratio of 1.86 (95% CI 1.44-2.39) [<a href="#rid62">62</a>]. In a study from rural Guinea-Bissau, which included 285 patients with HIV-2 and 117 patients with HIV-1 with up to 19 years of follow-up, the median time to death for individuals with HIV-2 and HIV-1 was approximately 15 and 7 years, respectively [<a href="#rid60">60</a>]. Another study reported the probability of survival in 133 individuals with HIV-2 stratified by viral load [<a href="#rid61">61</a>]. Among the 85 patients with a detectable HIV-2 viral load (&gt;100 copies/mL), the median time to death was about 7.5 years for those in the high viral load strata (&gt;10,000 copies/mL) and about 11 years for those in the medium viral load strata (101 to 10,000 copies/mL). In the natural history study comparing HIV-1 and HIV-2 infection described above, the median survival time after HIV infection was significantly longer for those with HIV-2 (15.6 versus 8.2 years) [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H60762000"><span class="h3">Lower levels of viremia</span><span class="headingEndMark"> — </span>When matched for disease stage, studies of persons living with HIV-2 infection demonstrate that plasma viremia is significantly lower compared to those with HIV-1 infection [<a href="#rid64">64</a>]. Low levels of viremia are also associated with slower declines of CD4 cell counts and lower rates of viral evolution among individual patients with HIV-2 infection compared with those with HIV-1 [<a href="#rid65">65</a>]. Lower levels of viremia are also seen among recent HIV-2 seroconverters; in one study, the viral load set point was approximately 28-fold lower after seroconversion among those with HIV-2 than with HIV-1 infection [<a href="#rid66">66</a>]. HIV-2-specific immune responses may help to control viremia in early stages of infection [<a href="#rid66">66-69</a>]. </p><p>However, for each logarithmic increase in viral load in patients with HIV-2, the rate of CD4 T cell decline is similar to that seen in patients with HIV-1 [<a href="#rid52">52</a>]. Thus, the level of viremia may influence the development of advanced immunodeficiency [<a href="#rid70">70</a>]. </p><p class="headingAnchor" id="H2600297"><span class="h2">Natural history among dually infected patients</span><span class="headingEndMark"> — </span>The natural history of HIV-1 infection may be altered by coinfection with HIV-2 [<a href="#rid60">60,62,66,71-78</a>]. As an example, a cohort study found that the median time to AIDS was longer in 32 patients with dual infection compared with 119 patients with HIV-1 alone (104 versus 68 months) [<a href="#rid77">77</a>]. Extended follow-up of this cohort found that mortality in dually infected individuals was also lower [<a href="#rid78">78</a>]. However, a meta-analysis that included data from six studies found no difference in mortality between those with dual infection compared with HIV-1 monoinfection (mortality rate ratio 1.11, 95% CI 0.95-1.30) [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H60762064"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The mechanisms underlying the divergent natural history patterns between HIV-1 and HIV-2 infections are unclear. </p><p>In patients with HIV-1 infection, systemic immune activation is an independent marker of disease progression [<a href="#rid79">79</a>]. Immune activation may result from microbial translocation of bacterial cell wall products (eg, lipopolysaccharide), which occurs secondary to HIV-related invasion and disruption of the gastrointestinal mucosa [<a href="#rid80">80,81</a>]. Cross-sectional studies of patients with HIV in the United States have demonstrated that different stages of HIV disease are associated with higher levels of circulating lipopolysaccharide (LPS) and markers of monocyte activation (sCD14) and decreased endotoxin core antibody (EndoCAb) levels [<a href="#rid79">79,82</a>]. However, one longitudinal study in Africa did not support a role for microbial translocation among African patients with HIV-1 infection [<a href="#rid83">83</a>]. These opposing observations may be related to different modes of transmission or differences in baseline cytokine levels due to chronic intestinal infections, which could alter the immune response to HIV-1 infection. </p><p>There are few studies that have examined the role of microbial translocation or chronic immune activation and disease progression in persons with HIV-1 and HIV-2 infection [<a href="#rid64">64,80,84-87</a>]. These observational studies have demonstrated the following key findings:</p><p class="bulletIndent1"><span class="glyph">●</span>Some studies have suggested that patients with HIV-2 may have lower levels of immune activation compared with those with HIV-1, thus accounting for slower rates of disease progression [<a href="#rid84">84</a>], while others have found comparable levels among patients with similar stages of clinical disease [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are also conflicting data as to whether there is a direct relationship between viral load and markers of T cell activation [<a href="#rid64">64,80,85-87</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, several studies do suggest that immune activation (as measured by the cellular expression of HLA-DR and CD38 on CD4+ and CD8+ T cells and T cell receptor excision DNA circle [TREC] levels) is directly associated with CD4+ T cell depletion in patients with HIV-2, as previously described in HIV-1 infection [<a href="#rid64">64,80,84,86</a>]. Another study that examined the role of microbial translocation found a direct correlation between increased LPS levels and loss of CD4 T cells in both those with HIV-1 and HIV-2 infection alike [<a href="#rid85">85</a>].</p><p></p><p>Emerging data from independent studies suggests that the HIV-2 capsid and its interaction with the host viral restriction factor TRIM5a may play a role in HIV-2's attenuated pathogenesis and reduced transmission compared to HIV-1 [<a href="#rid88">88-90</a>].</p><p class="headingAnchor" id="H603396"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Similar to HIV-1, HIV-2 was initially a zoonosis, originally transmitted from West African Sooty mangabeys to humans. (See <a class="local">'Origin of the epidemic'</a> above.)</p><p></p><p class="bulletIndent1">HIV-2 is endemic in West Africa, but has also been reported in more than two dozen countries on every continent except Antarctica. Accurate estimates on the number of cases worldwide are lacking. (See <a class="local">'HIV-2 outside West Africa'</a> above.)</p><p></p><p class="bulletIndent1">Dual infection with HIV-1 and HIV-2 can occur in locales where both viruses cocirculate. (See <a class="local">'Dual infection with HIV-1 and HIV-2'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transmission</strong> – HIV-1 and HIV-2 share similar routes of transmission including sexual contact, blood-borne exposure (eg, blood transfusions, shared needles) and perinatal transmission. (See <a class="local">'Transmission'</a> above.)</p><p></p><p class="bulletIndent1">Transmission of HIV-2 appears to be less efficient than HIV-1. This observation may be related to the lower levels of plasma viremia and genital shedding that is observed among patients with HIV-2. (See <a class="local">'Transmission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural history</strong> – Multiple studies suggest that HIV-2 is generally less pathogenic than HIV-1. Compared with HIV-1, HIV-2 infection is characterized by a longer asymptomatic stage of infection, slower declines of CD4 cell counts and lower levels of plasma viremia. (See <a class="local">'Natural history'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis 2011; 52:780.</a></li><li><a class="nounderline abstract_t">Gottlieb GS, Raugi DN, Smith RA. 90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. Lancet HIV 2018; 5:e390.</a></li><li><a class="nounderline abstract_t">Ariën KK, Abraha A, Quiñones-Mateu ME, et al. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 2005; 79:8979.</a></li><li class="breakAll">UNAIDS. Available at: http://www.unaids.org/en/. (Accessed on February 20, 2023).</li><li class="breakAll">The World Health Organization. HIV/AIDS fact sheet. https://www.who.int/news-room/fact-sheets/detail/hiv-aids (Accessed on September 21, 2020).</li><li><a class="nounderline abstract_t">Cot MC, Poulain M, Delagneau JF, et al. Dual HIV-1 and HIV-2 infection in West Africa supported by synthetic peptide analysis. AIDS Res Hum Retroviruses 1988; 4:239.</a></li><li><a class="nounderline abstract_t">Evans LA, Moreau J, Odehouri K, et al. Simultaneous isolation of HIV-1 and HIV-2 from an AIDS patient. Lancet 1988; 2:1389.</a></li><li><a class="nounderline abstract_t">Rayfield M, De Cock K, Heyward W, et al. Mixed human immunodeficiency virus (HIV) infection in an individual: demonstration of both HIV type 1 and type 2 proviral sequences by using polymerase chain reaction. J Infect Dis 1988; 158:1170.</a></li><li><a class="nounderline abstract_t">Barin F, M'Boup S, Denis F, et al. Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of west Africa. Lancet 1985; 2:1387.</a></li><li><a class="nounderline abstract_t">Clavel F, Guétard D, Brun-Vézinet F, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986; 233:343.</a></li><li><a class="nounderline abstract_t">Gao F, Yue L, Robertson DL, et al. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol 1994; 68:7433.</a></li><li><a class="nounderline abstract_t">Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999; 397:436.</a></li><li><a class="nounderline abstract_t">Gao F, Yue L, White AT, et al. Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature 1992; 358:495.</a></li><li><a class="nounderline abstract_t">Kawamura M, Yamazaki S, Ishikawa K, et al. HIV-2 in west Africa in 1966. Lancet 1989; 1:385.</a></li><li><a class="nounderline abstract_t">Lemey P, Pybus OG, Wang B, et al. Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci U S A 2003; 100:6588.</a></li><li><a class="nounderline abstract_t">Wertheim JO, Worobey M. Dating the age of the SIV lineages that gave rise to HIV-1 and HIV-2. PLoS Comput Biol 2009; 5:e1000377.</a></li><li><a class="nounderline abstract_t">van der Loeff MF, Awasana AA, Sarge-Njie R, et al. Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. Int J Epidemiol 2006; 35:1322.</a></li><li><a class="nounderline abstract_t">Eholié S, Anglaret X. Commentary: decline of HIV-2 prevalence in West Africa: good news or bad news? Int J Epidemiol 2006; 35:1329.</a></li><li><a class="nounderline abstract_t">da Silva ZJ, Oliveira I, Andersen A, et al. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS 2008; 22:1195.</a></li><li><a class="nounderline abstract_t">Hamel DJ, Sankalé JL, Eisen G, et al. Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res Hum Retroviruses 2007; 23:1189.</a></li><li><a class="nounderline abstract_t">Fryer HR, Van Tienen C, Van Der Loeff MS, et al. Predicting the extinction of HIV-2 in rural Guinea-Bissau. AIDS 2015; 29:2479.</a></li><li><a class="nounderline abstract_t">Olesen JS, Jespersen S, da Silva ZJ, et al. HIV-2 continues to decrease, whereas HIV-1 is stabilizing in Guinea-Bissau. AIDS 2018; 32:1193.</a></li><li><a class="nounderline abstract_t">Larsen O, da Silva Z, Sandström A, et al. Declining HIV-2 prevalence and incidence among men in a community study from Guinea-Bissau. AIDS 1998; 12:1707.</a></li><li><a class="nounderline abstract_t">Remy G. HIV-2 infection throughout the world. A geographical perspective. Sante 1998; 8:440.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control (CDC). AIDS due to HIV-2 infection--New Jersey. MMWR Morb Mortal Wkly Rep 1988; 37:33.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). HIV-2 Infection Surveillance--United States, 1987-2009. MMWR Morb Mortal Wkly Rep 2011; 60:985.</a></li><li><a class="nounderline abstract_t">Peruski AH, Wesolowski LG, Delaney KP, et al. Trends in HIV-2 Diagnoses and Use of the HIV-1/HIV-2 Differentiation Test - United States, 2010-2017. MMWR Morb Mortal Wkly Rep 2020; 69:63.</a></li><li class="breakAll">Shah SS, Fine SM, Vail RM, et al. Diagnosis and Management of HIV-2 in Adults [Internet]. Baltimore (MD): Johns Hopkins University; 2022 Aug. Available from: https://www.ncbi.nlm.nih.gov/books/NBK558318/.</li><li><a class="nounderline abstract_t">Torian LV, Eavey JJ, Punsalang AP, et al. HIV type 2 in New York City, 2000-2008. Clin Infect Dis 2010; 51:1334.</a></li><li><a class="nounderline abstract_t">Léonard G, Chaput A, Courgnaud V, et al. Characterization of dual HIV-1 and HIV-2 serological profiles by polymerase chain reaction. AIDS 1993; 7:1185.</a></li><li><a class="nounderline abstract_t">Walther-Jallow L, Andersson S, da Silva Z, Biberfeld G. High concordance between polymerase chain reaction and antibody testing of specimens from individuals dually infected with HIV types 1 and 2 in Guinea-Bissau, West Africa. AIDS Res Hum Retroviruses 1999; 15:957.</a></li><li><a class="nounderline abstract_t">Sarr AD, Hamel DJ, Thior I, et al. HIV-1 and HIV-2 dual infection: lack of HIV-2 provirus correlates with low CD4+ lymphocyte counts. AIDS 1998; 12:131.</a></li><li><a class="nounderline abstract_t">Ishikawa K, Fransen K, Ariyoshi K, et al. Improved detection of HIV-2 proviral DNA in dually seroreactive individuals by PCR. AIDS 1998; 12:1419.</a></li><li><a class="nounderline abstract_t">Travers K, Mboup S, Marlink R, et al. Natural protection against HIV-1 infection provided by HIV-2. Science 1995; 268:1612.</a></li><li><a class="nounderline abstract_t">Schim van der Loeff MF, Aaby P, Aryioshi K, et al. HIV-2 does not protect against HIV-1 infection in a rural community in Guinea-Bissau. AIDS 2001; 15:2303.</a></li><li><a class="nounderline abstract_t">Wiktor SZ, Nkengasong JN, Ekpini ER, et al. Lack of protection against HIV-1 infection among women with HIV-2 infection. AIDS 1999; 13:695.</a></li><li><a class="nounderline abstract_t">Norrgren H, Andersson S, Biague AJ, et al. Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, west Africa: no protection of HIV-2 against HIV-1 infection. AIDS 1999; 13:701.</a></li><li><a class="nounderline abstract_t">U.S. Public Health Service guidelines for testing and counseling blood and plasma donors for human immunodeficiency virus type 1 antigen. MMWR Recomm Rep 1996; 45:1.</a></li><li><a class="nounderline abstract_t">Meda N, Ndoye I, M'Boup S, et al. Low and stable HIV infection rates in Senegal: natural course of the epidemic or evidence for success of prevention? AIDS 1999; 13:1397.</a></li><li><a class="nounderline abstract_t">Schutz R, Savarit D, Kadjo JC, et al. Excluding blood donors at high risk of HIV infection in a west African city. BMJ 1993; 307:1517.</a></li><li><a class="nounderline abstract_t">Kanki PJ, Travers KU, MBoup S, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343:943.</a></li><li><a class="nounderline abstract_t">Comparison of vertical human immunodeficiency virus type 2 and human immunodeficiency virus type 1 transmission in the French prospective cohort. The HIV Infection in Newborns French Collaborative Study Group. Pediatr Infect Dis J 1994; 13:502.</a></li><li><a class="nounderline abstract_t">Adjorlolo-Johnson G, De Cock KM, Ekpini E, et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994; 272:462.</a></li><li><a class="nounderline abstract_t">Prazuck T, Yameogo JM, Heylinck B, et al. Mother-to-child transmission of human immunodeficiency virus type 1 and type 2 and dual infection: a cohort study in Banfora, Burkina Faso. Pediatr Infect Dis J 1995; 14:940.</a></li><li><a class="nounderline abstract_t">Gottlieb GS, Hawes SE, Agne HD, et al. Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS 2006; 20:895.</a></li><li><a class="nounderline abstract_t">Burgard M, Jasseron C, Matheron S, et al. Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1. Clin Infect Dis 2010; 51:833.</a></li><li><a class="nounderline abstract_t">O'Donovan D, Ariyoshi K, Milligan P, et al. Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia. MRC/Gambia Government/University College London Medical School working group on mother-child transmission of HIV. AIDS 2000; 14:441.</a></li><li><a class="nounderline abstract_t">Ter Schiphorst E, Hansen KC, Holm M, Hønge BL. Mother-to-child HIV-2 transmission: comparison with HIV-1 and evaluation of factors influencing the rate of transmission. A systematic review. Trans R Soc Trop Med Hyg 2022; 116:399.</a></li><li><a class="nounderline abstract_t">Hawes SE, Sow PS, Stern JE, et al. Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding. AIDS 2008; 22:2517.</a></li><li><a class="nounderline abstract_t">Simon F, Matheron S, Tamalet C, et al. Cellular and plasma viral load in patients infected with HIV-2. AIDS 1993; 7:1411.</a></li><li><a class="nounderline abstract_t">Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587.</a></li><li><a class="nounderline abstract_t">Gottlieb GS, Sow PS, Hawes SE, et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 2002; 185:905.</a></li><li><a class="nounderline abstract_t">Gilbert PB, McKeague IW, Eisen G, et al. Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med 2003; 22:573.</a></li><li><a class="nounderline abstract_t">MacNeil A, Sarr AD, Sankalé JL, et al. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol 2007; 81:5325.</a></li><li><a class="nounderline abstract_t">Popper SJ, Sarr AD, Travers KU, et al. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 1999; 180:1116.</a></li><li><a class="nounderline abstract_t">Poulsen AG, Aaby P, Larsen O, et al. 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Lancet 1997; 349:911.</a></li><li><a class="nounderline abstract_t">Martinez-Steele E, Awasana AA, Corrah T, et al. Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS 2007; 21:317.</a></li><li><a class="nounderline abstract_t">Esbjörnsson J, Månsson F, Kvist A, et al. Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study. Lancet HIV 2018.</a></li><li><a class="nounderline abstract_t">Schim van der Loeff MF, Jaffar S, Aveika AA, et al. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia. AIDS 2002; 16:1775.</a></li><li><a class="nounderline abstract_t">van Tienen C, Schim van der Loeff M, Peterson I, et al. HTLV-1 and HIV-2 infection are associated with increased mortality in a rural West African community. PLoS One 2011; 6:e29026.</a></li><li><a class="nounderline abstract_t">van der Loeff MF, Larke N, Kaye S, et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology 2010; 7:46.</a></li><li><a class="nounderline abstract_t">Prince PD, Matser A, van Tienen C, et al. Mortality rates in people dually infected with HIV-1/2 and those infected with either HIV-1 or HIV-2: a systematic review and meta-analysis. AIDS 2014; 28:549.</a></li><li class="breakAll">Esbjörnsson J, Månsson F, Kvist A, et al. High rate of disease progression in untreated HIV-2 infection. Presented at the Conference on Retroviruses and Opportunistic Infections (CROI), 2017. Seattle, Washington, Febrary 13-16. Abstract #37. http://www.croiconference.org/sessions/high-rate-disease-progression-untreated-hiv-2-infection.</li><li><a class="nounderline abstract_t">Sousa AE, Carneiro J, Meier-Schellersheim M, et al. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002; 169:3400.</a></li><li><a class="nounderline abstract_t">MacNeil A, Sankale JL, Meloni ST, et al. Long-term intrapatient viral evolution during HIV-2 infection. J Infect Dis 2007; 195:726.</a></li><li><a class="nounderline abstract_t">Andersson S, Norrgren H, da Silva Z, et al. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med 2000; 160:3286.</a></li><li><a class="nounderline abstract_t">Leligdowicz A, Yindom LM, Onyango C, et al. Robust Gag-specific T cell responses characterize viremia control in HIV-2 infection. J Clin Invest 2007; 117:3067.</a></li><li><a class="nounderline abstract_t">Duvall MG, Jaye A, Dong T, et al. Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection. J Immunol 2006; 176:6973.</a></li><li><a class="nounderline abstract_t">Angin M, Wong G, Papagno L, et al. Preservation of Lymphopoietic Potential and Virus Suppressive Capacity by CD8+ T Cells in HIV-2-Infected Controllers. J Immunol 2016; 197:2787.</a></li><li><a class="nounderline abstract_t">Matheron S, Pueyo S, Damond F, et al. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS 2003; 17:2593.</a></li><li><a class="nounderline abstract_t">Nkengasong JN, Kestens L, Ghys PD, et al. Dual infection with human immunodeficiency virus type 1 and type 2: impact on HIV type 1 viral load and immune activation markers in HIV-seropositive female sex workers in Abidjan, Ivory Coast. AIDS Res Hum Retroviruses 2000; 16:1371.</a></li><li><a class="nounderline abstract_t">Greenberg AE. Possible protective effect of HIV-2 against incident HIV-1 infection: review of available epidemiological and in vitro data. AIDS 2001; 15:2319.</a></li><li><a class="nounderline abstract_t">Alabi AS, Jaffar S, Ariyoshi K, et al. Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients. AIDS 2003; 17:1513.</a></li><li><a class="nounderline abstract_t">Koblavi-Dème S, Kestens L, Hanson D, et al. Differences in HIV-2 plasma viral load and immune activation in HIV-1 and HIV-2 dually infected persons and those infected with HIV-2 only in Abidjan, Côte D'Ivoire. AIDS 2004; 18:413.</a></li><li><a class="nounderline abstract_t">Borget MY, Diallo K, Adje-Toure C, et al. Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, Côte d'Ivoire. J Clin Virol 2009; 45:72.</a></li><li><a class="nounderline abstract_t">Landman R, Damond F, Gerbe J, et al. Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients. AIDS 2009; 23:426.</a></li><li><a class="nounderline abstract_t">Esbjörnsson J, Månsson F, Kvist A, et al. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N Engl J Med 2012; 367:224.</a></li><li><a class="nounderline abstract_t">Esbjörnsson J, Månsson F, Kvist A, et al. Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals. AIDS 2014; 28:949.</a></li><li><a class="nounderline abstract_t">Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365.</a></li><li><a class="nounderline abstract_t">Leligdowicz A, Feldmann J, Jaye A, et al. Direct relationship between virus load and systemic immune activation in HIV-2 infection. J Infect Dis 2010; 201:114.</a></li><li><a class="nounderline abstract_t">Levy JA. HIV pathogenesis: 25 years of progress and persistent challenges. AIDS 2009; 23:147.</a></li><li><a class="nounderline abstract_t">Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008; 3:e2516.</a></li><li><a class="nounderline abstract_t">Redd AD, Dabitao D, Bream JH, et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc Natl Acad Sci U S A 2009; 106:6718.</a></li><li><a class="nounderline abstract_t">Michel P, Balde AT, Roussilhon C, et al. Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: correlation of T cell apoptosis with beta2 microglobulin concentration and disease evolution. J Infect Dis 2000; 181:64.</a></li><li><a class="nounderline abstract_t">Nowroozalizadeh S, Månsson F, da Silva Z, et al. Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. J Infect Dis 2010; 201:1150.</a></li><li><a class="nounderline abstract_t">Hegedus A, Nyamweya S, Zhang Y, et al. Protection versus pathology in aviremic and high viral load HIV-2 infection-the pivotal role of immune activation and T-cell kinetics. J Infect Dis 2014; 210:752.</a></li><li><a class="nounderline abstract_t">Buggert M, Frederiksen J, Lund O, et al. CD4+ T cells with an activated and exhausted phenotype distinguish immunodeficiency during aviremic HIV-2 infection. AIDS 2016; 30:2415.</a></li><li><a class="nounderline abstract_t">Ramalingam VV, Subramanian S, Fletcher GJ, et al. Interaction of human immunodeficiency virus-1 and human immunodeficiency virus-2 capsid amino acid variants with human tripartite motif 5α protein SPRY domain and its association with pathogenesis. Indian J Med Microbiol 2019; 37:574.</a></li><li><a class="nounderline abstract_t">Zuliani-Alvarez L, Govasli ML, Rasaiyaah J, et al. Evasion of cGAS and TRIM5 defines pandemic HIV. Nat Microbiol 2022; 7:1762.</a></li><li><a class="nounderline abstract_t">Boswell MT, Nazziwa J, Kuroki K, et al. Intrahost evolution of the HIV-2 capsid correlates with progression to AIDS. Virus Evol 2022; 8:veac075.</a></li></ol></div><div id="topicVersionRevision">Topic 13966 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21367732" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Update on human immunodeficiency virus (HIV)-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30052509" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994792" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994792" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994792" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3207511" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Dual HIV-1 and HIV-2 infection in West Africa supported by synthetic peptide analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2904524" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Simultaneous isolation of HIV-1 and HIV-2 from an AIDS patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3058815" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mixed human immunodeficiency virus (HIV) infection in an individual: demonstration of both HIV type 1 and type 2 proviral sequences by using polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2867393" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of west Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2425430" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Isolation of a new human retrovirus from West African patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7933127" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9989410" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1641038" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Human infection by genetically diverse SIVSM-related HIV-2 in west Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2563537" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : HIV-2 in west Africa in 1966.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12743376" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Tracing the origin and history of the HIV-2 epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19412344" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Dating the age of the SIV lineages that gave rise to HIV-1 and HIV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16543363" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16847021" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Commentary: decline of HIV-2 prevalence in West Africa: good news or bad news?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18525265" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17961103" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26485121" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Predicting the extinction of HIV-2 in rural Guinea-Bissau.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29683842" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : HIV-2 continues to decrease, whereas HIV-1 is stabilizing in Guinea-Bissau.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9764792" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Declining HIV-2 prevalence and incidence among men in a community study from Guinea-Bissau.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9917568" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : HIV-2 infection throughout the world. A geographical perspective</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3122008" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : AIDS due to HIV-2 infection--New Jersey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21796096" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : HIV-2 Infection Surveillance--United States, 1987-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31971928" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Trends in HIV-2 Diagnoses and Use of the HIV-1/HIV-2 Differentiation Test - United States, 2010-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31971928" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Trends in HIV-2 Diagnoses and Use of the HIV-1/HIV-2 Differentiation Test - United States, 2010-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21039219" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : HIV type 2 in New York City, 2000-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8216974" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Characterization of dual HIV-1 and HIV-2 serological profiles by polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10445807" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : High concordance between polymerase chain reaction and antibody testing of specimens from individuals dually infected with HIV types 1 and 2 in Guinea-Bissau, West Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9468361" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : HIV-1 and HIV-2 dual infection: lack of HIV-2 provirus correlates with low CD4+ lymphocyte counts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9727562" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Improved detection of HIV-2 proviral DNA in dually seroreactive individuals by PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7539936" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Natural protection against HIV-1 infection provided by HIV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11698704" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : HIV-2 does not protect against HIV-1 infection in a rural community in Guinea-Bissau.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10397564" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Lack of protection against HIV-1 infection among women with HIV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10397565" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, west Africa: no protection of HIV-2 against HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8604210" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : U.S. Public Health Service guidelines for testing and counseling blood and plasma donors for human immunodeficiency virus type 1 antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10449294" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Low and stable HIV infection rates in Senegal: natural course of the epidemic or evidence for success of prevention?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8274919" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Excluding blood donors at high risk of HIV infection in a west African city.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7909009" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Slower heterosexual spread of HIV-2 than HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8078737" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Comparison of vertical human immunodeficiency virus type 2 and human immunodeficiency virus type 1 transmission in the French prospective cohort. The HIV Infection in Newborns French Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8040982" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8584359" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Mother-to-child transmission of human immunodeficiency virus type 1 and type 2 and dual infection: a cohort study in Banfora, Burkina Faso.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549974" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20804413" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770548" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia. MRC/Gambia Government/University College London Medical School working group on mother-child transmission of HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34791488" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mother-to-child HIV-2 transmission: comparison with HIV-1 and evaluation of factors influencing the rate of transmission. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19005275" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7904166" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cellular and plasma viral load in patients infected with HIV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7915856" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Reduced rate of disease development after HIV-2 infection as compared to HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920314" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12590415" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17329334" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10479138" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9093252" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17255738" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30392769" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12218389" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22194980" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : HTLV-1 and HIV-2 infection are associated with increased mortality in a rural West African community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20482865" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23921613" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Mortality rates in people dually infected with HIV-1/2 and those infected with either HIV-1 or HIV-2: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23921613" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Mortality rates in people dually infected with HIV-1/2 and those infected with either HIV-1 or HIV-2: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12218162" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17262716" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Long-term intrapatient viral evolution during HIV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11088091" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17823657" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Robust Gag-specific T cell responses characterize viremia control in HIV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16709858" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27566819" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Preservation of Lymphopoietic Potential and Virus Suppressive Capacity by CD8+ T Cells in HIV-2-Infected Controllers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14685053" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11018856" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Dual infection with human immunodeficiency virus type 1 and type 2: impact on HIV type 1 viral load and immune activation markers in HIV-seropositive female sex workers in Abidjan, Ivory Coast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11698707" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Possible protective effect of HIV-2 against incident HIV-1 infection: review of available epidemiological and in vitro data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12824789" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15090792" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Differences in HIV-2 plasma viral load and immune activation in HIV-1 and HIV-2 dually infected persons and those infected with HIV-2 only in Abidjan, Côte D'Ivoire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19375979" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, Côte d'Ivoire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19114866" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22808957" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24812673" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17115046" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Microbial translocation is a cause of systemic immune activation in chronic HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19938978" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Direct relationship between virus load and systemic immune activation in HIV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19098484" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : HIV pathogenesis: 25 years of progress and persistent challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18575590" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19357303" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10608752" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: correlation of T cell apoptosis with beta2 microglobulin concentration and disease evolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20199244" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24803534" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Protection versus pathology in aviremic and high viral load HIV-2 infection-the pivotal role of immune activation and T-cell kinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27525551" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : CD4+ T cells with an activated and exhausted phenotype distinguish immunodeficiency during aviremic HIV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32436883" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Interaction of human immunodeficiency virus-1 and human immunodeficiency virus-2 capsid amino acid variants with human tripartite motif 5αprotein SPRY domain and its association with pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36289397" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Evasion of cGAS and TRIM5 defines pandemic HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36533148" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Intrahost evolution of the HIV-2 capsid correlates with progression to AIDS.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
